Fujifilm Irvine Scientific, Inc., a provider of cell culture solutions for both the life science and medical markets, is growing its Armstrong R&D Center of Excellence at its California HQ. Construction—which began this past October and is expected to be completed by January 2022—represents the company’s commitment to the progression of discovery research, bioproduction, cell and gene therapy, assisted reproductive technologies and cytogenetics in its life sciences and medical media divisions.
Among the additions, the firm says that the expansion will benefit a variety of programs and initiatives, including manufacturing sciences and technologies (MSAT), single-use technology development, and automation platforms for media development.
“With society’s increasing demand for global access to more high-quality, cost-effective vaccines, biopharmaceuticals, cell-based therapies, gene therapies and in-vitro fertilization procedures, the need for a broadened focus on innovation is pivotal to expedite critical product and technology development,” notes Bob Newman, Fujifilm Irvine Scientific’s chief science officer. “The expansion project will more than double the R&D facility’s footprint, and will allow for more enhanced technical collaboration between R&D experts and customers to develop personalized solutions and enhance partnership opportunities.”